Navigation Links
Multiple Presentations Confirm Clinical Efficacy and High Rate of Patient Compliance Using Provent® Sleep Apnea Therapy to Treat Obstructive Sleep Apnea
Date:6/14/2011

BELMONT, Calif., June 14, 2011 /PRNewswire/ -- Ventus Medical, Inc. today announced that several independent board-certified sleep specialists presented positive clinical data supporting use of Provent® Sleep Apnea Therapy in their obstructive sleep apnea patients. These presentations, at SLEEP 2011, the 25th Annual Meeting of the Associated Professional Sleep Societies in Minneapolis, Minnesota, highlight the clinical efficacy and high compliance rate for patients with obstructive sleep apnea (OSA) using Provent Therapy.

(Photo: http://photos.prnewswire.com/prnh/20110209/SF45785-b)

(Photo: http://photos.prnewswire.com/prnh/20110209/SF45785-a)

"Together, these presentations provide conclusive evidence from clinical practices throughout the United States that Provent Therapy offers an effective treatment option for patients with obstructive sleep apnea who are not compliant on CPAP therapy," said Philip Westbrook, M.D., Chief Medical Officer of Ventus Medical and Emeritus Clinical Professor of Medicine at the University of California, Los Angeles. "In addition to the consistent evidence of reduced apnea hypopnea index (AHI) and Epworth sleepiness scale (ESS), the presentations today include positive long-term (12-month) Provent Therapy results. We are excited to see how Provent Therapy is being used by sleep specialists across the country and incorporated into their therapeutic protocols for untreated patients suffering from obstructive sleep apnea."

Oral Presentation Highlights Use of Provent Therapy over 12-Month Duration

Meir Kryger, M.D., of Gaylord Sleep Medicine in Wallingford, CT presented data from a 13-center, 12-month prospective study. Results showed that patients treated with Provent Therapy over a period of 12-months reduced their AHI by 70 percent. AHI is a measure of h
'/>"/>

SOURCE Ventus Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
2. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
3. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
4. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
5. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
6. Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device
7. Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011
10. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
11. Reportlinker Adds Epidemiology: Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... -- CVS Health Corporation (NYSE: CVS ) will ... 2015, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will be ... CVS Health website for all interested parties. To access ... be archived and available on the web site for ...
(Date:4/17/2015)... , April 17, 2015 ... EGFR mutation   is a viable alternative to tumour biopsy ... testing in all patients with advanced NSCLC   ... effectiveness of plasma circulating tumour DNA (ctDNA) testing for epidermal ... with advanced non-small cell lung cancer (NSCLC) in clinical practice. ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Mammography Equipment - Global Strategic Business Report" ... analyzes the worldwide markets for Mammography Equipment in US$ ... and Digital Mammography Equipment. The report provides separate comprehensive ... Japan , Europe ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... BioVex Inc, a company developing next generation biologics ... announced today that the results from a Phase I/II combination ... will be presented at the 2009 American Society of Clinical ... 2009 - June 2, 2009 in Orlando, FL. The results ...
... on BIBW 2992, an Irreversible, Dual EGFR / HER2 ... NSCLC Patients with EGFR Activating Mutations - (1,2)-The First ... Conn., May 14 Boehringer Ingelheim will present new ... 2992 and BIBF 1120 at the 2009 Annual Meeting ...
Cached Medicine Technology:BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 2BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 3BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10
(Date:4/18/2015)... (PRWEB) April 18, 2015 “ ArcAngel ” ... which takes a look at the latest and coolest ... Joe Troohey, the host of AppWatch and technology expert, conducted ... a personal safety app. , In a turbulent world, ... help. Calling 911 should always be their first move, but ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital at ... were all selected as Top Workplaces in Tampa Bay. ... is ranked number one for large businesses according to ... in partnership with an independent research firm. Florida Hospital ... opened in October of 2012 with a vision of ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
Breaking Medicine News(10 mins):Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3
... system of this mosquito is of great importance as scientists ... of viruses that cause yellow and dengue fevers ... genes that make up the immune system of the Aedes ... been identified. ,This study is the first of ...
... the airplane, is about to be connected, allowing travellers to ... off cell phones and fasten seatbelts are a familiar ... European company has found a way to make dialling safe ... ,"Cabin connectivity is here and GSM phone use is both ...
... a healthy diet rich in fish and nuts could be ... to prostate cancer, new US research indicates . A study ... Investigation found that omega-3 fatty acids found in the foods ... to the condition. Working with mice genetically engineered to develop ...
... an ancient retrovirus that infected chimps and other primates millions ... species is susceptible to HIV, said a study released Thursday. ... against a four-million-year-old virus, called Pan troglodytes endogenous retrovirus, or ... most retroviruses, it inserts its DNA into the genome of ...
... urate in the blood is linked to a reduced risk ... at the Harvard School of Public Health (HSPH), was led ... ,Urate is a normal component of blood, and although ... beneficial effects because it is a potent antioxidant. ...
... Thursday said that all villages affected by chikungunya fever ... spread awareness among people even as 17,000 suspected ... this year. ,'We have asked the nine chikungunya-affected ... National Rural Health Mission, we will provide Rs.10,000 each ...
Cached Medicine News:Health News:Aedes Agypti Mosquitos Immune System Revealed 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 3Health News:Ancient Viral Defense may Explain Susceptibility to HIV: Study 2Health News:High Urate Levels in Blood Linked to Reduced Parkinson's Risk 2Health News:Chikungunya-hit Villages to Get Funds to Fight Mosquitoes 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: